François Raffi1, Yazdan Yazdanpanah2, Francis Fagnani3, Caroline Laurendeau3, Antoine Lafuma4, Julie Gourmelen5. 1. Department of Infectious Diseases, University Hospital, Nantes, France. 2. ATIP-AVENIR Inserm 'Modélisation, Aide à la Décision, et Coût-Efficacité en Maladie Infectieuses', IAME, UMR 1137 INSERM, Univ Paris Diderot, Sorbonne Paris Cité, Paris, France Service de Maladies Infectieuses et Tropicales, Hôpital Bichat Claude Bernard, Paris, France. 3. Cemka Eval, Bourg-la-Reine, France. 4. Cemka Eval, Bourg-la-Reine, France antoine.lafuma@cemka.fr. 5. UMS011 INSERM - UVSQ 'Cohortes en population', Hôpital Paul Brousse, Villejuif, France.
Abstract
OBJECTIVES: To compare adherence and persistence (continuous treatment with a prescribed medication) in HIV adult patients who received combination ART (cART) as a once-daily single-tablet regimen (STR) versus other administration schedules. METHODS: A representative random sample of the French National Healthcare Insurance Database was used. Adherence and persistence were compared according to their administration schedules using χ(2) and survival analyses. STRs were marketed in France in 2009 and the study period was selected to allow a sufficient number of patients with an STR and a relevant duration of follow-up. RESULTS: During the period covered (2006-11), 362 HIV-positive adult antiretroviral-naive patients (566 lines of treatments) were selected. The mean rates of adherence were 89.6% for the STR (tenofovir/emtricitabine/efavirenz; n = 76), 86.4% for cART with >1 pill once daily (n = 242) and 77.0% for cART with >1 daily intake (n = 248; P < 0.0001 versus STR). Kaplan-Meier estimations of persistence after 2 years of treatment were 79.1% for the STR, 53.3% for cART with >1 pill once daily and 51.8% for cART with >1 daily intake (P = 0.001; log-rank test). Sensitivity analyses confirmed these results. After excluding treatment sequences showing a switch from tenofovir/emtricitabine plus efavirenz to the similar STR, the rates of persistence were 80.3% for the STR (n = 60), 77.3% for atazanavir-containing cART (n = 96) and 68.3% for darunavir-containing cART (n = 56) at 18 months (global P = 0.006). CONCLUSIONS: These results suggest that persistence is higher in HIV patients treated with an STR compared with other administration schedules. Significant benefit in terms of adherence was observed with the STR in comparison with regimens with >1 daily intake but no difference was observed when comparing with regimens involving >1 pill once daily.
OBJECTIVES: To compare adherence and persistence (continuous treatment with a prescribed medication) in HIV adultpatients who received combination ART (cART) as a once-daily single-tablet regimen (STR) versus other administration schedules. METHODS: A representative random sample of the French National Healthcare Insurance Database was used. Adherence and persistence were compared according to their administration schedules using χ(2) and survival analyses. STRs were marketed in France in 2009 and the study period was selected to allow a sufficient number of patients with an STR and a relevant duration of follow-up. RESULTS: During the period covered (2006-11), 362 HIV-positive adult antiretroviral-naive patients (566 lines of treatments) were selected. The mean rates of adherence were 89.6% for the STR (tenofovir/emtricitabine/efavirenz; n = 76), 86.4% for cART with >1 pill once daily (n = 242) and 77.0% for cART with >1 daily intake (n = 248; P < 0.0001 versus STR). Kaplan-Meier estimations of persistence after 2 years of treatment were 79.1% for the STR, 53.3% for cART with >1 pill once daily and 51.8% for cART with >1 daily intake (P = 0.001; log-rank test). Sensitivity analyses confirmed these results. After excluding treatment sequences showing a switch from tenofovir/emtricitabine plus efavirenz to the similar STR, the rates of persistence were 80.3% for the STR (n = 60), 77.3% for atazanavir-containing cART (n = 96) and 68.3% for darunavir-containing cART (n = 56) at 18 months (global P = 0.006). CONCLUSIONS: These results suggest that persistence is higher in HIV patients treated with an STR compared with other administration schedules. Significant benefit in terms of adherence was observed with the STR in comparison with regimens with >1 daily intake but no difference was observed when comparing with regimens involving >1 pill once daily.
Authors: Bora Youn; Theresa I Shireman; Yoojin Lee; Omar Galárraga; Aadia I Rana; Amy C Justice; Ira B Wilson Journal: AIDS Date: 2017-07-31 Impact factor: 4.177
Authors: Seble G Kassaye; Zehava Grossman; Maya Balamane; Betsy Johnston-White; Chenglong Liu; Princy Kumar; Mary Young; Michael C Sneller; Irini Sereti; Robin Dewar; Catherine Rehm; William Meyer; Robert Shafer; David Katzenstein; Frank Maldarelli Journal: Clin Infect Dis Date: 2016-06-15 Impact factor: 9.079
Authors: Yuehan Zhang; Tracey E Wilson; Adebola Adedimeji; Daniel Merenstein; Joel Milam; Jennifer Cohen; Mardge Cohen; Elizabeth T Golub Journal: AIDS Behav Date: 2018-03
Authors: Babatunde Akinwunmi; Daniel Buchenberger; Jenny Scherzer; Martina Bode; Paolo Rizzini; Fabio Vecchio; Laetitia Roustand; Gaelle Nachbaur; Laurent Finkielsztejn; Vasiliki Chounta; Nicolas Van de Velde Journal: Eur J Public Health Date: 2021-07-13 Impact factor: 3.367
Authors: Johanna Boretzki; Eva Wolf; Carmen Wiese; Sebastian Noe; Annamaria Balogh; Anja Meurer; Ivanka Krznaric; Alexander Zink; Christian Lersch; Christoph D Spinner Journal: Patient Prefer Adherence Date: 2017-11-08 Impact factor: 2.711
Authors: Olivier Ségéral; Eric Nerrienet; Sansothy Neth; Bruno Spire; Vohith Khol; Laurent Ferradini; Saramony Sarun; Chandara Mom; Sopheak Ngin; Charlotte Charpentier; Pagnaroat Men; Marion Mora; Vun Mean Chhi; Penhsun Ly; Vonthanak Saphonn Journal: Front Public Health Date: 2018-03-19
Authors: Martina Penazzato; Devasena Gnanashanmugam; Pablo Rojo; Marc Lallemant; Linda L Lewis; Francesca Rocchi; Agnes Saint Raymond; Nathan Ford; Rohan Hazra; Carlo Giaquinto; Yodit Belew; Diana M Gibb; Elaine J Abrams Journal: Clin Infect Dis Date: 2017-06-01 Impact factor: 9.079